Table 1_NSAID use may decrease serum Klotho levels.docx by Jingchao Yan (14079168)

“…Subgroup analyses did not reveal any statistically significant interactions.</p>Conclusion<p>Contrary to previous speculations, the use of NSAIDs is associated with a decrease in serum Klotho levels.…”

Loss of Vps34 is associated with decreased eTreg survival but intact activation. by Erienne G. Norton (9612079)

Comparison of (a) Chao index and (b) Shannon diversity index of the fecal microbiota in WT and Lep KO mice. by Yu Sang Choi (22656230)

Aβ and vGlut2 staining of 6-, 9-, and 12-month dLGN sections show significant plaque load and accelerated loss of retinal ganglion cell axon terminals in the 5xFAD mice. by Shaylah McCool (20818280)

Genes with highest fold change in exponential compared to stationary phase. Genes with >10 fold enrichment are shown, ribosomal genes are highlighted with bolded text. <i>rpsJ</i>/... by Justin Greene (306625)

Subjects:

National age-standardized rates of DALYs and ASDR of IHD attributable to HSBP and their estimated annual percentage changes in 2021. by Zhenhua Zhuang (11192745)

Subjects:

Age-specific burden of IHD attributable to HSBP for males and females in 2021. by Zhenhua Zhuang (11192745)

Subjects:

Global burden of IHD attributable to HSBP from 1990 to 2021. by Zhenhua Zhuang (11192745)

Subjects:

Age-specific estimated annual percentage changes in DALYs and death rates for 21 regions from 1990 to 2021. by Zhenhua Zhuang (11192745)

Subjects:

SDI-based age-standardized rates of DALYs and ASDR for IHD attributable to HSBP. by Zhenhua Zhuang (11192745)

Subjects:

A mathematical model of PIF4 autoregulation captures the experimental observations of hypocotyl growth and promoter activity. by Sreya Das (20531295)

Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations. by Denis Mustafov (19137870)

“…<p><b>(A)</b> A significant reduction in colony-forming ability was observed in U87MG cells treated with 100ΜM SHG-44 compared to 100ΜM cis-platin and the untreated control. …”

Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. by Masashi Okawa (8951294)

Subjects:

The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. by Masashi Okawa (8951294)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. by Masashi Okawa (8951294)

Subjects: